Does Anavar Raise Oestrogen? The SHBG Crash, the T:E2 Ratio Shift, and Why You Get Gyno Symptoms on a Non-Aromatising Steroid
Anavar does not aromatise. This is one of its most cited pharmacological advantages: oxandrolone cannot be converted to oestradiol by the aromatase enzyme, which means it should not, in theory, produce any oestrogen-related side effects. Yet users consistently report symptoms that look and feel oestrogenic: nipple sensitivity, mild gynaecomastia, mood changes consistent with elevated oestrogen, and water retention patterns that do not match what a non-aromatising compound should produce. The explanation for this apparent contradiction lies not in Anavar and oestrogen directly, but in what Anavar does to SHBG and how that alters the balance between free testosterone and free oestradiol in your body. At Hemi Pharma UK, we cover this mechanism in full because it directly affects how you manage oestrogen during any cycle that includes oxandrolone.
The paradox operates through two distinct pathways depending on whether you are running Anavar alongside a testosterone base or running it alone. Both pathways produce oestrogen-related symptoms through mechanisms that have nothing to do with Anavar aromatising. Understanding which pathway applies to your protocol determines whether the solution is adjusting your aromatase inhibitor dose, adjusting your testosterone dose, or simply accepting that the symptoms are transient and will resolve post-cycle.
How Does SHBG Determine the Balance Between Free Testosterone and Free Oestradiol?
Sex hormone-binding globulin is a plasma glycoprotein produced by the liver that binds circulating sex hormones with high affinity. The critical detail for understanding the Anavar and oestrogen paradox is that SHBG does not bind all sex hormones equally. Its binding affinity follows a strict hierarchy: dihydrotestosterone binds with the highest affinity, followed by testosterone, and then oestradiol. Specifically, DHT binds SHBG with approximately 5 times the affinity of testosterone and approximately 20 times the affinity of oestradiol.
This differential binding has a direct consequence. At any given SHBG concentration, a higher proportion of circulating testosterone is bound to SHBG compared to oestradiol. In a healthy male with normal SHBG, approximately 44% of testosterone is bound to SHBG, 54% is bound to albumin (loosely), and only 2% circulates freely. For oestradiol, the proportions are different: approximately 37% bound to SHBG, 60% to albumin, and 2 to 3% free. The free fraction is what reaches tissue receptors and produces biological effects.
Now consider what happens when SHBG drops dramatically. With SHBG suppressed, both testosterone and oestradiol are released from binding. But because testosterone was more heavily bound to SHBG in the first place, the proportional increase in free testosterone is larger than the proportional increase in free oestradiol. In isolation, this would seem favourable: more free testosterone relative to free oestradiol. The complication arises when SHBG suppression occurs alongside changes in total hormone production, which is exactly what happens during an Anavar cycle.
Why Does Anavar Plus Testosterone Produce Oestrogen Symptoms When Anavar Cannot Aromatise?
This is the most common scenario in which users experience the Anavar and oestrogen paradox, and the mechanism is straightforward once you trace the chain of events.
When you run Anavar alongside testosterone cypionate or testosterone enanthate, the oxandrolone suppresses SHBG dramatically. Clinical data shows SHBG can fall to single digits (nmol/L) during oxandrolone administration. This SHBG crash liberates a much larger fraction of your injected testosterone into the free, bioavailable pool.
More free testosterone means more substrate available for the aromatase enzyme in peripheral tissues (primarily adipose tissue). Aromatase converts testosterone to oestradiol. With more free testosterone reaching aromatase-expressing tissues, more oestradiol is produced. Simultaneously, the oestradiol that is produced is also less bound (because SHBG is suppressed), which means a higher proportion reaches oestrogen receptors in breast tissue and other target organs.
The net result is this: a dose of testosterone that did not produce oestrogen symptoms before adding Anavar begins to produce them after Anavar is introduced. The testosterone dose has not changed. The aromatase activity has not changed. What changed is the SHBG level, which altered how much of your testosterone reaches aromatase and how much of the resulting oestradiol reaches tissue receptors. The European Academy of Andrology’s clinical practice guidelines on gynaecomastia confirm that the fundamental mechanism of gynaecomastia involves an increase in the oestrogen-to-androgen balance, with SHBG alterations being one of the established pathways through which this imbalance occurs (Kanakis et al., 2019).
The practical solution is to reduce the testosterone dose or add a low-dose aromatase inhibitor such as anastrozole at 0.25mg to 0.5mg every other day. As detailed in our Anavar bloodwork guide, mid-cycle oestradiol testing is essential for calibrating this. If oestradiol is above 50 pg/mL and symptoms are present, a modest AI dose addresses the problem. If oestradiol is in range but symptoms persist, the cause may be a transient T:E2 ratio shift rather than absolute oestrogen elevation, and AI use is not indicated.
Why Does an Anavar Only Cycle Also Produce Oestrogen-Like Symptoms?
The second scenario is more confusing and less commonly understood. Users running Anavar without a testosterone base (which we recommend against for reasons covered in our Anavar only cycle article) sometimes report nipple sensitivity or mood symptoms suggestive of oestrogen dominance. This occurs despite the fact that both testosterone and oestradiol production are falling simultaneously.
The explanation lies in the rate at which testosterone and oestradiol decline, and the ratio between them. When oxandrolone suppresses the HPT axis, LH drops and testicular testosterone production falls. Oestradiol, which is produced primarily through aromatisation of testosterone, also falls. But the two do not necessarily fall at the same rate. Aromatase activity in adipose tissue is not directly suppressed by oxandrolone, so the percentage of remaining testosterone that gets converted to oestradiol may actually increase as total testosterone falls.
The result is a shifting T:E2 ratio that can transiently favour oestrogen dominance even though absolute oestradiol levels are lower than baseline. A 2024 review of the endocrine mechanisms of gynaecomastia in Biomedicines confirmed that gynaecomastia can develop not only from absolute oestrogen elevation but from a relative increase in the oestrogen-to-androgen ratio, with even modest shifts in this ratio being sufficient to stimulate breast tissue proliferation in susceptible individuals (PMC, 2024).
This is why some users report gyno-like symptoms on an Anavar only cycle despite no aromatising compound being present. It is not that Anavar raised oestrogen. It is that Anavar removed testosterone faster than oestradiol fell, creating a window of relative oestrogen dominance. This window is transient: as oestradiol production eventually catches down to match the suppressed testosterone, the ratio normalises. But during that transition period (typically weeks 3 to 5 of an Anavar-only cycle), the symptoms can be distressing.
How Do You Test for This on Bloodwork and What Should the Numbers Show?
The standard mid-cycle panel (as described in our Anavar bloodwork guide) includes oestradiol (E2) measurement. For interpreting the Anavar and oestrogen interaction, you need three markers: total testosterone, free testosterone (or calculated from total T, SHBG, and albumin), and oestradiol.
In a male running Anavar alongside a testosterone base at 150mg weekly, a typical mid-cycle picture would show: total testosterone in the 600 to 1200 ng/dL range (reflecting the exogenous dose), SHBG suppressed to single digits or low teens, free testosterone disproportionately elevated (because SHBG is so low), and oestradiol in the 30 to 60 pg/mL range. If oestradiol is above 50 pg/mL with symptoms present, the SHBG-mediated amplification is likely the cause, and a small AI dose is appropriate.
In a male running Anavar alone, the mid-cycle picture would show: total testosterone in the hypogonadal range (often below 200 ng/dL), SHBG suppressed, LH near zero, and oestradiol low but potentially not as low as expected relative to testosterone. The T:E2 ratio is the diagnostic clue: in a healthy male, the normal T:E2 ratio is approximately 14:1 to 20:1. If mid-cycle bloodwork shows a ratio closer to 5:1 or below despite both values being in the low range, the relative oestrogen dominance is confirmed. The solution in this case is not an AI (which would suppress already-low oestradiol further and worsen symptoms), but adding a testosterone base to restore the androgenic side of the ratio, or discontinuing the Anavar-only approach entirely.
Does Proviron Solve the Anavar Oestrogen Problem?
Proviron (mesterolone) is sometimes used alongside Anavar specifically because of its strong SHBG binding affinity. Published binding affinity data shows that mesterolone (1-alpha-methyl-DHT) binds SHBG with approximately 4 times the affinity of DHT, making it one of the highest-affinity SHBG ligands among commonly used AAS. In theory, Proviron displaces both testosterone and oestradiol from SHBG binding sites, further increasing the free fractions of both.
This creates a double-edged effect. On the positive side, Proviron’s strong androgenic activity at tissue level (including breast tissue, where it competes with oestradiol at the receptor) can counteract oestrogenic symptoms directly. Mesterolone binds the androgen receptor in breast tissue and opposes oestrogen-driven proliferation. On the negative side, the additional SHBG displacement can increase free oestradiol further, potentially exacerbating the underlying ratio problem in users who are already producing more oestradiol than they can manage.
The net effect of adding Proviron to an Anavar cycle depends on the individual’s oestrogen management. If oestradiol is controlled (either through low-dose AI or through a modest testosterone base that does not produce excessive aromatisation), Proviron’s androgenic effects at breast tissue are beneficial. If oestradiol is already elevated and SHBG is already suppressed, adding another SHBG-lowering agent may make the problem worse before it makes it better. The decision should be guided by mid-cycle bloodwork, not by assumption.
Frequently Asked Questions
Does Anavar directly raise oestrogen levels?
No. Oxandrolone cannot be converted to oestradiol by aromatase because it is a dihydrotestosterone derivative with a modified A-ring that aromatase cannot act upon. Anavar does not directly raise oestrogen. What it does is suppress SHBG, which indirectly increases the bioavailable fraction of any oestradiol already circulating or being produced from co-administered testosterone. The oestrogen-related symptoms users experience are caused by this indirect mechanism, not by Anavar itself aromatising.
Should I take an aromatase inhibitor during an Anavar cycle?
Only if you are co-administering a testosterone base and bloodwork confirms oestradiol elevation above 50 pg/mL. If you are running Anavar alongside testosterone, anastrozole at 0.25mg every other day is a reasonable starting point, titrated based on mid-cycle oestradiol testing. If you are running Anavar alone (not recommended), an AI will suppress your already-declining oestradiol further and worsen symptoms. The correct intervention for an Anavar-only oestrogen imbalance is adding a testosterone base, not suppressing oestrogen further.
Why did I get puffy nipples on Anavar when my friend on the same dose had no symptoms?
Individual susceptibility to oestrogenic effects at breast tissue varies significantly based on oestrogen receptor density, aromatase activity (which correlates with body fat percentage), baseline SHBG levels, and genetic predisposition to gynaecomastia. Two users on the same Anavar and testosterone protocol can have different oestradiol levels, different free oestradiol fractions, and different breast tissue sensitivity. The Kanakis et al. (2019) EAA guidelines note that gynaecomastia develops from an increase in the oestrogen-to-androgen balance, and the threshold at which this balance triggers breast tissue proliferation varies between individuals.
Will my oestrogen go back to normal after stopping Anavar?
Yes. The SHBG suppression that drives the Anavar and oestrogen paradox reverses once oxandrolone is cleared from your system. SHBG begins to recover within 1 to 2 weeks of cessation, and the free hormone fractions normalise accordingly. If you are running PCT with tamoxifen, the SERM also provides direct anti-oestrogenic activity at breast tissue during the recovery period, offering protection against any residual oestrogen-related symptoms while the HPT axis recovers.
Can high oestrogen from the SHBG crash cause fat gain during an Anavar cycle?
Elevated free oestradiol can promote subcutaneous fat deposition and water retention, both of which can blunt the visual cutting effect that Anavar is used for. However, the magnitude of oestrogen-driven fat gain during a 6 to 8 week cycle is modest compared to the repartitioning effect of oxandrolone itself. The more relevant concern is subcutaneous water retention, which can mask the muscle definition improvements that Anavar produces. Controlling oestradiol through AI dosing or testosterone dose adjustment prevents this masking effect and allows the full visual benefit of the cycle to express itself.